Mitochondrial involvement in genetically determined transition metal toxicity. I. Iron toxicity

Chemico-Biological Interactions

Volumn 163, Issue 1-2, 2006, Pages 68-76

  Huang, Xi Ping ^a,b   O'Brien, Peter J ^b   Templeton, Douglas M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Genetic disease; Iron metabolism; Iron toxicity; Mitochondrial genetics; Mitochondrial iron

Indexed keywords

CERULOPLASMIN; CYTOCHROME; FERROPORTIN 1; FLUROTHYL; HEMOJUVELIN; HEPCIDIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; TRANSITION ELEMENT;

ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON ENERGY LOSS SPECTROSCOPY; ELECTRON TRANSPORT; ERYTHROPOIETIC PROTOPORPHYRIA; FENTON REACTION; FRIEDREICH ATAXIA; GENE; GENE DELETION; GENE MUTATION; GENETIC DISORDER; GENETICS; HEMOCHROMATOSIS; HISTOLOGY; HOMEOSTASIS; HUMAN; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; SIDEROBLASTIC ANEMIA;

ANIMALS; DNA, MITOCHONDRIAL; HUMANS; IRON; IRON METABOLISM DISORDERS; MITOCHONDRIA;

ATAXIA;

EID: 33749666969     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.05.007     Document Type: Article

References (92)

1. Harris W.R. Iron chemistry. In: Templeton D.M. (Ed). Molecular and Cellular Iron Transport (2002), Marcel Dekker, New York 1-40
2. Halliwell B., and Gutteridge J.M.C. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186 (1990) 1-88
3. Halliwell B., and Gutteridge J.M.C. Biologically relevant metal ion-dependent hydroxyl radical generation. An update. FEBS Lett. 307 (1992) 108-112
4. Hentze M.W., Muckenthaler M.U., and Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 (2004) 285-297
5. Marx J.J.M., and Hider R.C. Iron: an essential but potentially harmful nutrient. Eur. J. Clin. Invest. 32 Suppl. 1 (2002) 1-2
6. Hershko C., Link G., and Cabantchik I. Pathophysiology of iron overload. Ann. N. Y. Acad. Sci. 850 (1998) 191-201
7. Hershko C., and Weatherall D.J. Iron-chelating therapy. CRC Crit. Rev. Clin. Lab. Sci. 26 (1988) 303-346
8. Kispal G., Csere P., Guiard B., and Lill R. The ABC transporter Atm1p is required for mitochondrial iron homeostasis. FEBS Lett. 418 (1997) 346-350
9. Babcock M., De Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., Pandolfo M., and Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276 (1997) 1709-1712
10. Cavadini P., Gellera C., Patel P.I., and Isaya G. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum. Mol. Genet. 9 (2000) 2523-2530
11. Ponka P. Iron utilization in erythrocyte formation and hemoglobin synthesis. In: Templeton D.M. (Ed). Molecular and Cellular Iron Transport (2002), Marcel Dekker, New York 643-677
12. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89 (1997) 1-25
13. Shaw G.C., Cope J.J., Li L., Corson K., Hersey C., Ackermann G.E., Gwynn B., Lambert A.J., Wingert R.A., Traver D., Trede N.S., Barut B.A., Zhou Y., Minet E., Donovan A., Brownlie A., Balzan R., Weiss M.J., Peters L.L., Kaplan J., Zon L.I., and Paw B.H. Mitoferrin is essential for erythroid iron assimilation. Nature 440 (2006) 96-100
14. Levi S., Corsi B., Bosisio M., Invernizzi R., Volz A., Sanford D., Arosio P., and Drysdale J. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 276 (2001) 24437-24440
15. Drysdale J., Arosio P., Invernizzi R., Cazzola M., Volz A., Corsi B., Biasiotto G., and Levi S. Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol. Dis. 29 (2002) 376-383
16. Agar J.N., Krebs C., Frazzon J., Huynh B.H., Dean D.R., and Johnson M.K. IscU is a scaffold for iron-sulfur cluster biosynthesis: sequential assembly of [2Fe-2S] and [4Fe-4S] clusters in IscU. Biochemistry 39 (2000) 7856-7862
17. Napier I., Ponka P., and Richardson D.R. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105 (2005) 1867-1874
18. Tong W.-H., and Rouault T. Distinct iron-sulfur cluster assembly complexes exist in the cytosol and mitochondria of human cells. EMBO J. 19 (2000) 5692-5700
19. Petrat F., de Groot H., Sustmann R., and Rauen U. The chelatable iron pool in living cells: a methodologically defined quantity. Biol. Chem. 383 (2002) 489-502
20. Kakhlon O., and Cabantchik Z.I. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med. 33 (2002) 1037-1046
21. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res. 531 (2003) 81-92
22. Richardson D.R., Ponka P., and Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 87 (1996) 3477-3488
23. M. Shvartsman, R.B. El, S. Epstejn, A. Shanzer, K. Raghavendra, A.M. Konijn, U. Rauen, R. Sustmann, I. Cabantchik, Iron can be delivered from plasma membrane to mitochondria via diffusion of chelator shielded complexes as viewed by live fluorescence imaging, First Congress of the International BioIron Society, Prague, May 22-26, 2005, Abstract 49.
24. Wickramasinghe S.N., Fulker M.J., Losowsky M.S., and Hall R. Microspectrophotometric and electron microscopic studies of bone marrow in hereditary sideroblastic anaemia. Acta Haematol. 45 (1971) 236-244
25. Grasso J.A., and Hines J.D. A comparative electron microscopic study of refractory and alcoholic sideroblastic anaemia. Br. J. Haematol. 17 (1969) 35-44
26. Rademakers L.H., Koningsberger J.C., Sorber C.W., Baart de la Faille H., Van Hattum J., and Marx J.J. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur. J. Clin. Invest. 23 (1993) 130-138
27. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., Rolandi V., Biasiotto G., Drysdale J., and Arosio P. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101 (2003) 1996-2000
28. van de Loosdrecht A.A., Brada S.J., Blom N.R., Hendriks D.W., Smit J.W., van den Berg E., de Wolf J.T., and Vellenga E. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk. Res. 25 (2001) 385-393
29. Inbal A., Avissar N., Shaklai M., Kuritzky A., Schejter A., Ben-David E., Shanske S., and Garty B.Z. Myopathy, lactic acidosis, and sideroblastic anemia: a new syndrome. Am. J. Med. Genet. 55 (1995) 372-378
30. Thakerngpol K., Fucharoen S., Boonyaphipat P., Srisook K., Sahaphong S., Vathanophas V., and Stitnimankarn T. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals 9 (1996) 177-183
31. Bradley J.L., Blake J.C., Chamberlain S., Thomas P.K., Cooper J.M., and Schapira A.H. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 9 (2000) 275-282
32. Tabrizi S.J., and Schapira A.H. Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem. Soc. Symp. 66 (1999) 99-110
33. Schipper H.M., Bernier L., Mehindate K., and Frankel D. Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. J. Neurochem. 72 (1999) 1802-1811
34. Schipper H.M., Vininsky R., Brull R., Small L., and Brawer J.R. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp. Neurol. 152 (1998) 188-196
35. Wang X., Manganaro F., and Schipper H.M. A cellular stress model for the sequestration of redox-active glial iron in the aging and degenerating nervous system. J. Neurochem. 64 (1995) 1868-1877
36. Ham D., and Schipper H.M. Heme oxygenase-1 induction and mitochondrial iron sequestration in astroglia exposed to amyloid peptides. Cell. Mol. Biol. (Noisy-le-grand) 46 (2000) 587-596
37. Mehindate K., Sahlas D.J., Frankel D., Mawal Y., Liberman A., Corcos J., Dion S., and Schipper H.M. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 77 (2001) 1386-1395
38. Lill R., Diekert K., Kaut A., Lange H., Pelzer W., Prohl C., and Kispal G. The essential role of mitochondria in the biogenesis of cellular iron-sulfur proteins. Biol. Chem. 380 (1999) 1157-1166
39. Rouault T.A., and Tong W.H. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell. Biol. 6 (2005) 345-351
40. Link G., Tirosh R., Pinson A., and Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127 (1996) 272-278
41. Britton R.S., Leicester K.S., and Bacon B.R. Iron toxicity and chelation therapy. Int. J. Hematol. 76 (2002) 219-228
42. Masini A., Ceccarelli D., Giovannini F., Montosi G., Garuti C., and Pietrangelo A. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and firosis in the liver of chronic iron-dosed gerbils: the effect of Silybin. J. Bioenerget. Biomembr. 32 (2000)
43. Link G., Saada A., Pinson A., Konijn A.M., and Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J. Lab. Clin. Med. 131 (1998) 466-474
44. Link G., Konijn A.M., and Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J. Lab. Clin. Med. 133 (1999) 179-188
45. Eaton J.W., and Qian M.W. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 32 (2002) 833-840
46. Salazar J.J., and Van Houten B. Preferential mitochondrial DNA injury caused by glucose oxidase as a steady generator of hydrogen eroxide in human fibroblasts. Mutat. Res. 385 (1997) 139-149
47. Yakes F.M., and Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 514-519
48. Palau F. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis. Int. J. Mol. Med. 7 (2001) 581-589
49. Delatycki M.B., Camakaris J., Brooks H., Evans-Whipp T., Thorburn D.R., Williamson R., and Forrest S.M. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45 (1999) 673-675
50. Montermini L., Rodius F., Pianese L., Molto M.D., Cossee M., Campuzano V., Cavalcanti F., Monticelli A., Palau F., Gyapay G., et al. The Friedreich ataxia critical region spans a 150-kb interval on chromosome 9q13. Am. J. Hum. Genet. 57 (1995) 1061-1067
51. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Canizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.L., Cocozza S., Koenig M., and Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
52. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., and Butterfield D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233 (2005) 145-162
53. Delatycki M.B., Williamson R., and Forrest S.M. Friedreich ataxia: an overview. J. Med. Genet. 37 (2000) 1-8
54. Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin. Investig. Drugs 12 (2003) 235-245
55. Forrest S.M., Knight M., Delatycki M.B., Paris D., Williamson R., King J., Yeung L., Nassif N., and Nicholson G.A. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics 1 (1998) 253-257
56. Durr A., Cossee M., Agid Y., Campuzano V., Mignard C., Penet C., Mandel J.L., Brice A., and Koenig M. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335 (1996) 1169-1175
57. Bidichandani S.I., Ashizawa T., and Patel P.I. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am. J. Hum. Genet. 62 (1998) 111-121
58. Gacy A.M., Goellner G.M., Spiro C., Chen X., Gupta G., Bradbury E.M., Dyer R.B., Mikesell M.J., Yao J.Z., Johnson A.J., Richter A., Melancon S.B., and McMurray C.T. GAA instability in Friedreich's Ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol. Cell 1 (1998) 583-593
59. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., and Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305 (2004) 242-245
60. Puccio H., and Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum. Mol. Genet. 9 (2000) 887-892
61. Cox T.C., Bawden M.J., Abraham N.G., Bottomley S.S., May B.K., Baker E., Chen L.Z., and Sutherland G.R. Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am. J. Hum. Genet. 46 (1990) 107-111
62. Aoki Y., Muranaka S., Nakabayashi K., and Ueda Y. delta-Aminolevulinic acid synthetase in erythroblasts of patients with pyridoxine-responsive anemia. Hypercatabolism caused by the increased susceptibility to the controlling protease. J. Clin. Invest. 64 (1979) 1196-1203
63. Harigae H., Furuyama K., Kimura A., Neriishi K., Tahara N., Kondo M., Hayashi N., Yamamoto M., Sassa S., and Sasaki T. A novel mutation of the erythroid-specific delta-aminolaevulinate synthase gene in a patient with X-linked sideroblastic anaemia. Br. J. Haematol. 106 (1999) 175-177
64. Allikmets R., Raskind W.H., Hutchinson A., Schueck N.D., Dean M., and Koeller D.M. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. 8 (1999) 743-749
65. Bekri S., Kispal G., Lange H., Fitzsimons E., Tolmie J., Lill R., and Bishop D.F. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 96 (2000) 3256-3264
66. Shimada Y., Okuno S., Kawai A., Shinomiya H., Saito A., Suzuki M., Omori Y., Nishino N., Kanemoto N., Fujiwara T., Horie M., and Takahashi E. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J. Hum. Genet. 43 (1998) 115-122
67. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., Dormishian F., Domingo Jr. R., Ellis M.C., Fullan A., Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P., Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C., Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E., Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T., Risch N.J., Bacon B.R., and Wolff R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13 (1996) 399-408
68. Feder J.N., Tsuchihashi Z., Irrinki A., Lee V.K., Mapa F.A., Morikang E., Prass C.E., Starnes S.M., Wolff R.K., Parkkila S., Sly W.S., and Schatzman R.C. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J. Biol. Chem. 272 (1997) 14025-14028
69. Pissia M., Polonifi K., Politou M., Lilakos K., Sakellaropoulos N., and Papanikolaou G. Prevalence of the G320V mutation of the HJV gene, associated with juvenile hemochromatosis, in Greece. Haematologica 89 (2004) 742-743
70. Lanzara C., Roetto A., Daraio F., Rivard S., Ficarella R., Simard H., Cox T.M., Cazzola M., Piperno A., Gimenez-Roqueplo A.P., Grammatico P., Volinia S., Gasparini P., and Camaschella C. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 103 (2004) 4317-4321
71. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., and Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480 (2000) 147-150
72. Ganz T., and Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. 290 (2006) G199-G203
73. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., Loukopoulos D., and Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 33 (2003) 21-22
74. Roetto A., Daraio F., Porporato P., Caruso R., Cox T.M., Cazzola M., Gasparini P., Piperno A., and Camaschella C. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood 103 (2004) 2407-2409
75. Kawabata H., Yang R., Hirama T., Vuong P.T., Kawano S., Gombart A.F., and Koeffler H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem. 274 (1999) 20826-20832
76. Fleming R.E., Migas M.C., Holden C.C., Waheed A., Britton R.S., Tomatsu S., Bacon B.R., and Sly W.S. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2214-2219
77. Mattman A., Huntsman D., Lockitch G., Langlois S., Buskard N., Ralston D., Butterfield Y., Rodrigues P., Jones S., Porto G., Marra M., De Sousa M., and Vatcher G. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 100 (2002) 1075-1077
78. Abboud S., and Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275 (2000) 19906-19912
79. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell. 5 (2000) 299-309
80. Wallace D.F., Pedersen P., Dixon J.L., Stephenson P., Searle J.W., Powell L.W., and Subramaniam V.N. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 100 (2002) 692-694
81. Hayashi A., Wada Y., Suzuki T., and Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am. J. Hum. Genet. 53 (1993) 201-213
82. Craven C.M., Alexander J., Eldridge M., Kushener J.P., Berstein S., and KKaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 3457-3461
83. Parkes J.G., and Templeton D.M. Transport of non-transferrin-bound iron by hepatocytes. In: Templeton D.M. (Ed). Molecular and Cellular Iron Transport (2002), Marcel Dekker, New York 451-466
84. Fox P.L. The copper-iron chronicles: the story of an intimate relationship. Biometals 16 (2003) 9-40
85. Harris E.D. Ceruloplasmin and iron: vindication after 30 years. Nutrition 15 (1999) 72-74
86. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., Gitschier J., and Anderson G.J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21 (1999) 195-199
87. Anderson G.J., Frazer D.M., McKie A.T., and Vulpe C.D. The ceruloplasmin homolog hephaestin and the control of intestinal iron absorption. Blood Cells Mol. Dis. 29 (2002) 367-375
88. Morita H., Ikeda S., Yamamoto K., Morita S., Yoshida K., Nomoto S., Kato M., and Yanagisawa N. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopaythological study of a Japanese family. Ann. Neurol. 37 (1995) 646-656
89. Harris Z.L., Klomp L.J., and Gitlin J.D. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr 67 Suppl. (1998) 972S-977S
90. Yonekawa M., Okabe T., Asamoto Y., and Ohta M. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur. Neurol. 42 (1999) 157-162
91. Nittis T., and Gitlin J.D. The copper-iron connection: hereditary aceruloplasminemia. Semin. Hematol. 39 (2002) 282-289
92. Hellman N.E., Schaefer M., Gehrke S., Stegen P., Hoffman W.J., Gitlin J.D., and Stremmel W. Hepatic iron overload in aceruloplasminaemia. Gut 47 (2000) 858-860